PRODUCTS
Trading
Tools
PLATFORMS
PRICING
PROMOTION
LEARN
HUB
More from Webull
- About us
Our Partners
- Wall Street Journal
SUPPORT

LTRN

Lantern Pharma Inc

3.42

-0.08-2.29%

After Hours: 3.450 +0.030 +0.88%16:38 09/06 EDT

Daily

Weekly

Monthly

Quarterly

Yearly

OPEN/PREV CLOSE3.500/3.500

TODAY RANGE3.250-3.590

VOL92.47K

MARKET CAP36.82M

52 WEEK RANGE2.380-11.99

AVG VOL (3M)62.95K

% TURNOVER0.86%

TURNOVER--

P/E (TTM)-2.0773

% RANGE9.71%

EPS(TTM)-1.6464

P/E(FORWARD)-1.5336

P/B1.190

BVPS2.875

DIVIDEND--

P/S1.195

BETA--

DIV YIELD0.00%

FREE FLOAT MKT CAP31.39M

SHARES OUTSTANDING10.76M

NEXT EARNINGS11/06-11/11

FREE FLOAT9.18M

LOT SIZE1

EX-DIV DATE--

News

Press Releases

Financial Reports

Profile

Latest

Popular

Benzinga·08/12 14:01
Watching Lantern Pharma; Zacks Small Cap Research Gives Stock $26 Price Valuation
Seeking Alpha·08/09 05:58
Lantern Pharma GAAP EPS of -$0.46 beats by $0.09
Press release·08/09 04:11
Based on the provided financial report articles, I generated the title for the article: **"Quarterly Financial Report for [Company Name] (Q2 2024)"** Please note that the title may not be exact, as the provided text does not contain the company name.
Investorplace·08/09 00:59
LTRN Stock Earnings: Lantern Pharma Beats EPS for Q2 2024
Benzinga·08/08 20:45
Lantern Pharma Q2 2024 GAAP EPS $(0.46) Beats $(0.55) Estimate
TipRanks·08/08 20:39
Lantern Pharma Q2 Results and LP-300 Clinical Trial Update
Reuters·08/08 20:01
LANTERN PHARMA REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS AND BUSINESS UPDATES
Dow Jones·08/08 20:01
Press Release: Lantern Pharma Reports Second Quarter 2024 Financial Results and Business Updates
Reuters·08/07 13:31
LANTERN PHARMA HIGHLIGHTS PROMISING PRECLINICAL RESULTS OF LP-184’S SYNERGY WITH CHECKPOINT INHIBITORS & SENSITIZING TUMORS THAT ARE NON-RESPONSIVE TO ANTI-PD1 THERAPY IN COLLABORATION WITH MD ANDERSON AT IMMUNO-ONCOLOGY SUMMIT 2024
Seeking Alpha·08/05 13:11
Lantern Pharma announces update from mid-stage trial for non-small cell lung cancer treatment
Benzinga·08/05 12:01
Lantern Pharma Shares Clinical Update From Ongoing Phase 2 HARMONIC Clinical Trial For Never Smokers With Advanced NSCLC, Including An 86% Clinical Benefit Rate In The Initial Patient Cohort
Reuters·08/05 12:00
LANTERN PHARMA INC - PRELIMINARY RESULTS SHOW CONSISTENT SAFETY PROFILES
Dow Jones·08/01 12:02
Press Release: Lantern Pharma to Report Second Quarter 2024 Operating & Financial Results on August 8th, 2024 at 4:30 p.m. ET
Reuters·07/10 12:30
LANTERN PHARMA ACHIEVES KEY MILESTONE TOWARDS DEVELOPMENT OF MOLECULAR DIAGNOSTIC FOR USE IN ONCOLOGY CLINICAL TRIALS FOR PATIENT SELECTION AND STRATIFICATION WITH DRUG CANDIDATE LP-184
Reuters·06/12 11:30
LANTERN PHARMA RECEIVES CERTIFICATE OF PATENT FROM JAPANESE PATENT OFFICE (JPO) FOR COMPOSITION OF MATTER COVERING DRUG CANDIDATE LP-284

Same Industry

Name/Symbol

Change%

Price

Lantern Pharma Inc

LTRN

-2.29%

3.420

Regeneron Pharmaceuticals

REGN

-1.66%

First Wave Biopharma Inc

ENTO

-2.30%

0.3950

BIONTECH

BNTX

-0.23%

89.94

United Therapeutics Corp.

UTHR

-1.25%

345.63

Siga Technologie

SIGA

-3.26%

7.71

Vertex Pharmaceuticals Inc

VRTX

-0.12%

468.00

Moderna

MRNA

-0.75%

72.89

Charles Riv Labs Intl Inc

CRL

-1.69%

187.96

Medpace Holdings

MEDP

-3.36%

335.74

Talphera Inc

TLPH

-1.98%

0.9900

ICON PLC

ICLR

-1.78%

302.52

China Biologic

CBPO

119.99

Iqvia Hldgs Inc

IQV

-2.04%

243.07

MOLECULAR PARTNERS AG

MOLN

-4.75%

5.51

Arcturus Therape

ARCT

-0.69%

18.69

Gilead Sciences Inc

GILD

-0.06%

78.72

PRA Health

PRAH

165.21

Aptevo Therapeutics Inc

APVO

-2.63%

0.3299

Incyte Corp

INCY

-2.70%

61.26

Biospecifics

BSTC

+0.15%

88.53